Crategutt®

Crategutt® informations

Schwabe

.

 

Crataegutt® - WS® 1442

for decreasing cardiac performance corresponding to stage II according to NYHA.

Active ingredient:

Dry extract from Hawthorn leaves with flowers WS®1442
Crataegutt® contains the special extract WS® 1442 from Hawthorn leaves with flowers. This extract is standardized to contain 18.75% of oligomeric procyanidins (OPCs). Crataegutt® increases the strength of the cardiac muscle, reduces the work load of the heart and adapts cardiac activity to the organism's requirements. Crataegutt® promotes coronary and myocardial blood flow and improves the oxygen utilization of the heart. Crataegutt® leads to an increase in cardiac performance and physical capacity. Crataegutt® is well tolerated and should be taken over a longer period of time.

Approved indication in Germany:

Decreasing cardiac performance corresponding to stage II according to NYHA.


Note: If conditions persist, are unclear or new, consult a doctor as diseases requiring medical clarification might be involved.

For information on precautions for use, side effects and contra-indications see the package leaflet or contact your doctor or pharmacist.

Data based on information issued 2008/05

Crataegutt® novo

Crataegutt® novo

Path Navigation

Main Navigation



Latest News

  • Ginkgo biloba extract is effective for cognitive decline

    Read more

Service Navigation

Help

You can change the Font Size here:

Font Size

Contactinformation

Dr. Willmar Schwabe Pharmaceuticals
Willmar-Schwabe-Straße 4
76227 Karlsruhe, Germany

Phone +49 (0) 7 21-40 05-1 01
Fax +49 (0) 7 21-40 05-2 02

www.schwabepharma.com